BAB VIII PENUTUP
B. Saran
1. Pemberian antiinflamasi deksametason dan azitromisin direkomendasikan sebagai terapi tambahan, sebagai pendamping antibiotik pada kasus pneumonia. Untuk pemberian pravastatin dapat dipertimbangkan sebagai antiinflamasi dalam tatalaksana pneumonia terutama pada kasus tanpa penyakit penyerta yang berat.
2. Perlu dilakukan penelitian multi center di Indonesia, karena pada penelitian ini pengaruh strain bakteri di sirkulasi berbeda antar lokasi, mungkin akan berpengaruh terhadap hasil terapi.
PNEUMONIA: adakah tempat untuk pemberian antiinflamasi ?
145
3. Perlu dilakukan penelitian lanjutan yaitu untuk kasus pneumonia rawat jalan, karena setting dari penelitian ini adalah rawat inap di rumah sakit.
PNEUMONIA: Adakah tempat untuk pemberian antiinflamasi ?
146
DAFTAR PUSTAKA
Abbas AK. 2012. Innate immunity. In: Abbas AK, Lichtman AH, Pillai S, editors. Cellular and molecular immunology. 7th edition. Philadelphia: Saunders
Elsevier. hlm. 55-88.
Abraham SM, Lawrence T, Kleiman A, Warden P, Medghalchi M, Tuckermann J, et al. 2006. Antiinflammatory effects of dexamethasone are partly dependent on induction of dual specificity phosphatase 1. JEM. vol. 203(8). hlm. 1883-9. Akram AR, Chalmers JD, Taylor JK, Rutherford J. 2013. An
evaluation of clinical stability criteria to predict hospital course in community-acquired pneumonia. Clin Microbiol Infect. vol.19. hlm. 1174–80.
Alcon A, Fabregas N, Torres A. 2005. Pathophysiology of pneumonia. Clin Chest Med. vol. 26. hlm. 39-46. Aliberti S, Peyrani P, Filardo G, Mirsaedi M, Amir A, Blasi F,
et al. 2011. Association between time to clinical stability and outcomes after discharge in hospitalized patients with community acquired pneumonia. Chest. vol. 140(2). hlm. 482-8.
Al-Shirawi N, Al-Jahdali H, Al Shimemeri A. 2006. Pathogenesis, etiology and treatment of bronchiectasis. Annals of Thorasic Medicine. vol 1. hlm. 41-51.
Amsden GW. 2005. Anti-inflammatory effects of macrolides- an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions. Journal of antimicrobial chemotherapy. vol. 55. hlm. 10-21.
Andrijevic I, Matijasevic J, Andrijevic L, Kovacevic T, Zaric B. 2014. Interleukin-6 and procalcitonin as biomarkers in mortality prediction of hospitalized patients with community acquired pneumonia. Annals of Thoracic Medicine. vol. 9. hlm. 162-167.
PNEUMONIA: adakah tempat untuk pemberian antiinflamasi ?
147
Arnold FW, Summersgill JT, Lajoie AS, Peyrani P, Marrie TJ, Rossi P. 2007. A worldwide perspective of atypical pathogens in community acquired pneumonia. Am J Respir Crit Care Med. vol.175. hlm. 1086-93. Azeem AAE, Hamdy G, Saraya M, Fawzy E, Anwar E,
Abdulattif S. 2013. The role of procalcitonin as a guide for the diagnosis, prognosis, and decision of antibiotic therapy for lower respiratory tract infections. Egyptian Journal of Chest Diseases and Tuberculosis. vol. 62. hlm. 687-95.
Azhdarzadeh M, Lotfipour F, Zakeri-milani P, Mohammadi G, Valizadeh H. 2012. Antibacterial performance of azithromycin nanoparticles as colloidal drug delivery system against different gram-negative and gram positive bacteria. Advanced pharmaceutical bulletin. vol. 2(1). hlm. 17-24. Bacci MR, Leme RCP, Zing NCP, Murad N, Adami F, Hinnig
PF, et al. 2015. Chagas ACP, Fonseca FLA. IL-6 and TNF-a serum levels are associated with early death in community-acquired pneumonia patients. Brazilian Journal of Medical and Biological Research. vol. 48(5). hlm. 427-32.
Balamayooran G, Batra S, Fessler MB, Happel KI, Jeyaseelan S. 2010. Mechanism of neutrophil accumulation in the lungs against bacteria. Am J Respir Cell Mol Biol. vol. 43. hlm. 5-16.
Baratawidjaja GK, Rengganis I. 2009. Imunologidasar. Edisi ke-8. Jakarta: FKUI. hlm. 226-8.
Barnes P. 1998. Antiinflammatory actions of glucocorticoids: molecularmechanisms. Clinical Science. vol. 94. hlm. 557-72.
Bbosa GS, Mwebaza N, Odda J, Kyegombe DB, Ntale M. 2014. Antibiotics/antibacterial drug use, their marketing and promotion during the post- antibiotic golden age and their role in emergence of bacterial resistance. I Health. vol. 6. hlm. 410-25.
PNEUMONIA: Adakah tempat untuk pemberian antiinflamasi ?
148
Bordon J, Aliberti S, Botran RF, Uriarte SM, Rane MJ, Duvvuri P, et al. 2012. Understanding the roles of cytokines and neutrophil activity and neutrophil apoptosis in the protective versus deleterious inflammatory response in pneumonia. International Journal of Infectious Diseases. vol. 17. hlm. 76-83. Borovac DN, Pejcic T, Petkovic TR, Dordevic D, Dordevic I,
Stankovic I, et al. 2011. Scientific Journal of the Faculty of Medicine. vol. 28. hlm. 147-54.
Boureux A, Vignal E, Faure S, Fort P. 2007. Evolution of the rho family of ras-like GTP-ases in eukaryotes. Mol. Biol. Evol. vol. 24(1). hlm. 203-16.
Bradley JR. 2008. TNF mediated inflammatory disease. Journal of Pathology. vol. 214. hlm. 149-60.
British Thoracic Society (BTS). 2009. Guidelines for the management of community in adults:update 2009. Thorax. vol. 64. hlm. 1-15.
Bulska M and Orszulak-michalak D. 2014. Immunomodulatory and antiinflamatory properties of macrolides. Curr issues pharm med sci. vol. 27. hlm. 61-4.
Caballero J and Rello J. 2011. Combination antibiotic therapy for community acquired pneumonia. Annals of intensive care. vol. 1. hlm. 48.
Chalmers JD, Short PM, Mandal P, Akram AR, Hill AT. 2010. Statins in community acquired pneumonia: evidence from experimental and clinical studies. Respiratory Medicine. vol. 104(8). hlm. 1081-91. Chamberlain RS, Shayota BJ, Nyberg C, Sridharan P. 2014.
The utilityof procalcitonin as a biomarker to limit the duration of antibiotic therapy in adult sepsis patients. Surgical Science. vol. 5. hlm. 342-53. Chambers HF. 2001. Antimicrobial agents: Protein
synthesis inhibitors and miscellaneous antibacterial agents. In: Hardman JG, Limbird LE,
editors. Goodman & Gilman’s the pharmacological
basis of therapeutics. 10th edition. McGraw-Hill.
PNEUMONIA: adakah tempat untuk pemberian antiinflamasi ?
149
Chopra V, Flanders SA. 2009. Does statin use improve pneumonia outcomes?. Chest. vol. 136. hlm. 1381- 88.
Chow CW, Moraes TJ, Downey GP. 2008. Host defenses. In: Albert RK, Spiro SG, Jett JR, editors. Clinical respiratory medicine. 3rd edition. Philadelphia:
Elsevier. hlm. 166-76.
Christ-Crain M, Mu¨ller B. 2007. Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators. Eur Respir J. vol. 30. hlm. 556–73.
Chun SK, Jessica KY, Richard MT, Rodrigo C, Sonal S, Yoon KL. 2012. Statins and associated risk of pneumonia: a systematicreview and meta-analysis of observational studies. Eur J Clin Pharmacol. vol. 68. hlm. 747–55.
Chung SD, Tsai MC, Lin HC, Kang JH. 2014. Statin use and clinical outcomes among pneumonia patients. Clin Microbiol Infect. vol. 20. hlm. 879-85.
Compos DB, Ibiapina CC. 2011. The role of macrolides in noncystic fibrosis bronchiectasis. Hindawi Publishing Corporation Pulmonary Medicin. vol. 4. hlm. 1-5.
Craig A, Mai J, Cai S, Jeyaseelan S. 2009. Neutrophil recruitment to the lungs during bacterial pneumonia. Infection and Immunity. vol. 77. hlm. 568-75.
Davies L, Angus RM, Calverley PM. 1999. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet. vol. 354. Hlm. 456-60. Gazzerro P, Proto MC, Gangemi G, Malfitano AM, Ciaglia E,
Pisanti S, et al. 2012. Pharmacological actions of statins: a critical appraisal in the management of cancer. vol. 64. hlm. 102-146.
PNEUMONIA: Adakah tempat untuk pemberian antiinflamasi ?
150
Ghanei M, Mehdi GZ, Majid S. 2005. Improvement of respiratory symptoms by long-term low-dose erythariomycin in sulfur mustard exposed cases: a pilot study. Journal of Medical Chemical, Biological, Radiological Defense. vol. 3. hlm. 1-9.
Goetz MB, Rhew DC, Torres A. 2005. Pyogenic bacterial pneumonia, lung abscess and empyema. In: Mason RJ, Broaddus VC, Murray JF, Nadel JA, editors. Murray and Nadels Textbook of Respiratory Medicine. 4th ed. Philladelphia:
Elsevier Inc. hlm. 979-1032.
Groenewegen KH, Schols AM, Wouters EF. 2008. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest. vol. 124. hlm. 459-67
Gupta P, Bhatia V. 2008. Corticosteroid physiology and principles of therapy. Indian Journal of Pediatrics. vol. 75(10). Hlm. 1039-44.
Guzman C, Calleros CH, Griego LL, Montor JM. 2010. Interleukin-6: a cytokine with a pleiotropic role in the neuroimmunoendocrine network. The Open Neuroendocrinology Journal. vol. 3. hlm. 152-160. Haworth CS, Bilton D Elborn JS. 2014. Long – term
macrolide maintenance therapy in non – cf bronchiectasis : evidence and questions. Respiratory Medicine. vol. 108. hlm. 1397-1408. Haworth CS. 2011. Antibiotics treatment strategies in
adults with bronchiectasis. Eur Respir Mon. vol. 52. hlm. 211-22.
Hedlun J, Hansson LO. 2000. Procalcitonin and c-reactive protein levels in community acquired pneumonia: correlation with etiology and prognosis. Infection. vol. 28. hlm. 68-73
Hilde HF, Bos WJ, Sabine CA, Rijkers GT, Biesma DH, Velzen-Blad H, et al. 2012. Dexamethasone Downregulates the Systemic Cytokine Response in Patients with Community-Acquired Pneumonia. Clinical and Vaccine Immunology. vol. 19(9). hlm. 1532-8.
PNEUMONIA: adakah tempat untuk pemberian antiinflamasi ?
151
Idriss HT, Naismith JH. 2013. TNF alpha and the TNF receptor superfamily: structure-function relationship(s). Microsc Res Tech. vol. 50(3). hlm. 184-95.
Irfan M, Farooqi J, Hasan R. 2013. Community acquired pneumonia. Curr Opin PulmMed. vol. 19. hlm. 1- 11.
Iwata A, Shirai R, Ishii H, Kushima H, Otani S, Hashinaga K. 2012. Inhibitory effect of statins on inflammatory cytokine production from human bronchial epithelial cells. Clinical and Experimental Immunology. vol. 168. hlm. 234-40.
Jain MK, Ridker PM. 2005. Antiinflammatory effects of statins: clinical evidence and basic mechanisms. Nature Reviews. vol. 4. hlm. 977-87.
Jenks K. 2008. Corticosteroid. editor, In: Clinical drug therapy. 6th edition.Philadelphia: Lipponcott. hlm. 352-72.
Kanoh S and Rubin BK. 2010. Mechanism of action and clinical application of macrolides as immunomodulatory medications. Clinical microbiology reviews. vol. 23(3). hlm. 590-615. Katzung B. 2006. Adenocortocosteroid and adrenocortical
antaogonis, editor. In:Basic and clinical pharmacology. 10th edition. Newyork: Mcgraw Hill. hlm. 1163-94.
Kiriyama Y, Nomura Y, Tokumitsu Y. 2002. Calcitonin gene expression induced by lipopolysaccharide in the rat pituitary. Am J Physiology Endocrinol Metab. vol. 282. hlm. 1380-4.
Kishimoto T. 2010. IL-6: from its discovery to clinical applications. International Immunology. vol. 22(5). hlm. 347-52.
Kolditz M, Ewig S, Hoffken G. 2013. Managementbased risk prediction in community-acquired pneumonia by scores and biomarkers. Eur Respir J. vol. 41. hlm. 974-84.
PNEUMONIA: Adakah tempat untuk pemberian antiinflamasi ?
152
Kosanke R, Beier W, Lipecky R, Meisner M. 2008. Clinical benefits of procalcitonin. Tanaffos. vol. 7. hlm. 14- 18.
Kristiansen OP, Mandrup-Poulsen T. 2005. Interleukin-6 and diabetes: the good, the bad, or the indifferent? Diabetes. Suppl. vol. 2. hlm. 114-24.
Lee H. 2013. Procalcitonin as a biomarker of infectious Diseases. Korean J Intern Med. vol. 28. hlm. 285- 91.
Lentino JR and Krasnicka B. 2002. Association between initial empirical therapy and decreased length of stay among veteran patients hospitalized with community acquired pneumonia. International journal of antimicrobial agents. vol. 19(1). hlm. 61- 6.
Liao JK, Laufs U. 2005. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. vol. 45. hlm. 89-118.
Lim WS, Macfarlane JT, Boswell TCJ, Harrison TG, Rose D, Leinonen M, et al. 2001. Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax. vol. 56. hlm. 296-301.
Lionakis M, Kontoyiannis D. 2003. Glucocorticoids and invasive fungal infections. Lancet. vol. 362. hlm. 1828-38.
Loecker ID, Preiser JC. 2012. Statins in the critically ill. Annals of Intensive Care. vol. 2. hlm. 1-12.
Lorenzo MJ, Moret I, Sarria B, Cases E, Cortijo J, Mendez R, et al. 2015. Lung inflammatory pattern and antibiotic treatment in pneumonia. Respiratory research. vol. 16. hlm. 15
Maitra A, Kumar V. The lung. 2007. In: Kumar, Abbas, Fausto, Mitchell, editors.Robbin Basic Pathology. 8th ed.Philladelphia: Saunders Elsevier. hlm. 508-
PNEUMONIA: adakah tempat untuk pemberian antiinflamasi ?
153
Makris D, Manoulakas E, Komnos A, Papakrivou E, Tzovaras N, Hovas A, et al. 2011. Effect of pravastatin on the frequency of ventilator- associated pneumonia and on intensive care unit mortality: Open-label, randomized study. Crit Care Med. vol. 39(11). hlm. 2440-46.
Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. 2007. Infectious diseases society of america/american thoracic societycon sensus guidelines on the management of community-acquired pneumonia in adults. Clinical Infectious Diseases. vol. 44. hlm. 27-72. Martinez R, Menedez R, Reyes S, Polverino E, Cilloniz C,
Martinez A, et al. 2011. Factors associated with inflammatory cytokine patterns in community- acquired pneumonia. Eur Respir J. vol. 37. hlm. 393-9.
Maruna P, Nedelkova K, Gurlich R. 2000. Physiology and genetics of procalsitonin. Physiol Res. vol. 49. hlm. 57-61.
Masakela R, Green RJ. 2012. The role of macrolides in childhood-non cystic fibrosis-related bronchiectasis. Hindawi Publishing Corporation
Mediators of Inflammation. hlm. 1-7.
Masia M, Gutierrez F, Shum C, Padilla S, Navarro JC, Flores E, et al. 2005. Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index. Chest. vol. 128. hlm. 2223–9.
Mason CM, Nelson S. 2005. Pulmonary host defenses and factors predisposing to lung infection. Clin Chest Med. vol. 26. hlm. 11-7.
Medchrome. Mechanism of action of steroid hormones: animation. [cited April 14th2015]. Available from: http://tube.medchrome.com/2011/10/mechanis m-of-action-of-steroid-hormones.html
Medzhitov R. 2010. Inflammation 2010: new adventures of an old flame. Cell. vol. 140. hlm. 771-6.
PNEUMONIA: Adakah tempat untuk pemberian antiinflamasi ?
154
Meijvis SCA, Hardeman H, Remmelts FH, Heijligenberg R, Rijkers GT, Velzen-Blad H, et al. 2011. Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. Lancet. vol. 377(9782). hlm. 2023-30.
Meijvis SCA, Van de Garde EMW, Rijkers GT, Bos WJW. 2012. Treatment with anti-inflammatory drugs in community acquired Pneumonia. J Intern Med. vol. 272. hlm. 25–35.
Meisner M. 2013. Current status of procalcitonin in the ICU. Neth J Crit Care. vol. 17(2). hlm. 4-12.
Menendez R, Torres A, Rodriguez de castro F, Zalacain R, Aspa J, Borderias L, et al. 2004. Reaching stability in community-acquired pneumonia: the effects of the severity of the disease, treatment, and the characteristics of patients. Clinical infectious diseases. vol. 39. hlm. 1783-90.
Meynaar IA, Droog W, Batstra M, Vreede R, Herbrink P. 2011. In critically ill patients, serum procalcitonin is more useful in differentiating between sepsis and SIRS than CRP, Il-6, or LBP. Critical Care Research and Practice. hlm. 1-6.
Mizgerd JP. 2008. Acute lower respiratory tract infection. N Engl J Med. vol. 358. hlm. 716-27.
Moldoveanu B, Otmishi P, Jani P, Walker J, Sarmiento X, Guardiola J, et al. 2009. Inflammatory mechanisms in the lung. Journal of inflammation research. vol.2. hlm. 1-11.
Mor A, Thomsen RW, Ulrichsen SP, Sorensen HT. 2013. Chronic heart failure and risk of hospitalization with pneumonia: a population-based study. European Journal of Internal Medicine. vol. 24. hlm. 349-53.
Mueller C, Muller B, Perruchoud AP. 2008. Biomarkers: past, present, and future. Swiss Med Wkly. vol. 138. hlm. 225-9.
PNEUMONIA: adakah tempat untuk pemberian antiinflamasi ?
155
Mukaida N. 2003. Pathophysiologycal roles of interleukin- 8/CXCL8 in pulmonary diseases. AJP Lung Cell Mol Physiol. vol. 284. hlm. 566-77.
Nakamura M, Kono R, Nomura S, Utsunomiya H. 2013. Procalcitonin: Mysterious Protein in Sepsis. Journal of Basic & Clinical Medicine. vol.2(1). hlm. 7-11.
Naugler EW, Karin M. 2007. The wolf in sheep’s clothing:
the role of interleukin-6 in immunity, inflammation and cancer. Trends In Molecular Medicine. vol. 12. hlm. 1-11.
Nicod LP. 2005. Lung defences: an overview. Eur Respir Rev. vol. 14. hlm. 45-50.
Novack V, Eisinger V, Frenkel A, Terblanche M, Adhikari NKJ, Douvdevani A, et al. 2009. The effects of statin therapy on inflammatory cytokines in patients with bacterial infections: a randomized double-blind placebo controlled clinical trial. Intensive Care Med. vol. 35. hlm. 1255-60.
Perhimpunan Dokter Paru Indonesia (PDPI). 2014. Pneumonia komunitas. Pedoman Diagnosis dan Penatalaksanaan di Indonesia. Jakarta: PDPI. Prasetyo SE, Reviono, Suradi. 2016. Pengaruh omega 3
fatty acid terhadap kadar prokalsitonin dan perbaikan klinis pada pasien pneumonia komunitas. J Respir Indo. vol. 36, hlm. 138-46. Purba JYL, Reviono, Suradi, Harsini, Aphridasari J. 2017.
Pengaruh pravastatin terhadap kadar IL-6, pro-CT, dan lama perbaikan klinis pada penderita pneumonia. J Respir Indo. vol. 37. hlm. 75-83.
Purba JYL. 2016. Pengaruh pravastatin terhadap kadar IL-6, pro-CT, dan lama perbaikan klinis pada
penderita pneumonia. Tesis. Program Pendidikan Dokter Spesialis Pulmonologi dan Kedokteran Respirasi. Fakultas Kedokteran. Universitas Sebelas Maret. Surakarta.
PNEUMONIA: Adakah tempat untuk pemberian antiinflamasi ?
156
Ramirez SH, Heilman D, Morsey B, Potula R, Haorah J, Persidsky Y. 2008. Activation of peroxisome proliferator-activated receptor γ (PPARγ) suppresses rho GTPases in human brain microvascular endothelial cells and inhibits adhesion and transendothelial migration of HIV-1 infected monocytes. J Immunol. vol. 180. hlm. 1854-65.
Reinhart K, Karzai W, Meisner M. 2000. Procalcitonin: a new marker of the systemic inflammatory response to infections. Intensive Care Med. vol. 26. hlm. 1193-1200.
Rhen T, Cidlowski JA. 2005. Antiinflammatory Action of Glucocorticoids - New Mechanisms for Old Drugs. N Engl J Med. vol. 353. hlm. 1711-23.
Rhren T, Cidlowski J. 2005. Antiinflamatory action of glucocorticoids newmechanisms for old drugs. New England Journal of Medicine. vol. 353. hlm. 1711- 23.
Rubin R. 2011. Adrenocortical hormones and drugs affecting the cortex adrenal, editor. In: Modern pharmacology with clinical application, 5th edition. Scheller J, Chalaris A, Arras DS, John SR. 2011. The pro and antiinflammatory properties of the cytokine interleukin-6. Biochimica et Biophysica Acta. vol. 1813. hlm. 878-88.
Schleicher GK, Herbert V, Brink A, Martin S, Maraj R, Galpin JS, et al. 2005. Procalcitonin and C- reactive protein levels in HIV-positive subjects with tuberculosis and pneumonia. European Respiratory Journal. vol. 25. hlm. 688-92.
Sevilla-sanchez D, Soy-muner D, Soler-porcar N. 2010. Usefulness of macrolides as anti-inflammatories in respiratory diseases. Arch bronchoneumol. vol. 46(5). hlm. 244-54.
Sharma S, Jaffe A, Dixon G. 2007. Immunomodulatory effects of macrolide antibiotics in respiratory disease: therapeutic implications for asthma and cystic fibrosis. Pediatric Drugs. vol. 9. hlm. 107-18.
PNEUMONIA: adakah tempat untuk pemberian antiinflamasi ?
157
Simanjutak LH. 2016. Pengaruh azitromisin dosis rendah terhadap lama waktu perbaikan klinis, kadar IL-8 dan neutrophil sputum penderita pneumonia. Tesis. Program Pendidikan Dokter Spesialis Pulmonologi dan Kedokteran Respirasi. Fakultas Kedokteran. Universitas Sebelas Maret. Surakarta. 2016.
Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. 2004. Serum procalcitonin and c-reactive protein levels as marker of bacterial infection : a systematic review and meta-analysis. CID. vol. 39. hlm. 206-16.
Sing B. Pengaruh kadar prokalsitonin dan TNF-α terhadap perbaikan klinis setelah pemberian deksametason selama lima hari pada pasien pneumonia. Tesis. Program Pendidikan Dokter Spesialis Pulmonologi dan Kedokteran Respirasi. FakultasKedokteran. UniversitasSebelasMaret. Surakarta. 2015.
Stancu C, Sima A. 2001. Statins: mechanism of action and effects. J Cell Mol Med. vol. 5(4). hlm. 378-87. Steel HC, Cockeran R, Anderson R, Feldman C. 2013.
Overview of community-acquired pneumonia and the role of inflammatory mechanisms in the immunopathogenesis of severe pneumococcal disease. Mediators of Inflammation. vol. 2013. hlm. 1-18.
Stellari FF, Sala A, Donofrio G, Ruscitti F, Caruso P, Topini TM, et al. 2014. Azithromycin inhibits nuclear factor-κB activation during lung inflammation: an in vivo imaging study. Pharma Res Per. vol. 2(5). hlm. 1-9.
Summah H, Qu JM. 2009. Biomarkers: a definite plus in pneumonia. Hindawi Publishing Corporation. vol. 9. hlm. 1-9.
PNEUMONIA: Adakah tempat untuk pemberian antiinflamasi ?
158
Surjanto E, Sutanto YS, Reviono, Harsini, Indrayati D. 2013. Perbandingan Tiga Metode Prediksi secara Retrospektif dalam Menilai Derajat Pneumonia Komunitas pada Pasien Lanjut Usia di Rumah Sakit Dr. Moewardi Surakarta. J Respir Indo. vol. 33. hlm. 34-9.
Tamaoki J. 2004. The effects of macrolides on inflammatory cells. Chest. vol. 125. hlm. 41-51.
Tamariz L, Hare HM. 2010. Inflammatory cytokines in heart failure: roles in aetiology and utility as biomarkers. European Heart Journal. vol. 31. hlm. 768-770. Tong L, Tergaonkar V. 2014. Rho protein GTPases and their
interactions with NFκβ: crossroads of inflammation and matrix biology. Biosci Rep. vol. 34(3). hlm. 283-95.
Tsang KWT, Ho PI, Chan KN, Lam WK, Yuen KY, Ooi GC. 1999. A Pilot study of low-dose erythariomycin in bronchiectasis. Eur Respir J. vol. 13. hlm. 361-4. Unger NR and Gauthier TP. 2015. Protein synthesis
inhibitors. In: Whalen K, Finkel R, Panavelil TA, editors. Lippincott illustrated reviews: pharmacology. 6th edition. Walters Kluwer. hlm.
499-512.
Vanaudenaerde BM, Robin V, Meyts I, Stephanie I, Vleeschauwer D, Verleden SE, et al. 2008. Makrolide therapy target a specific phenotype in respiratory medicine: from clinical experience to basic science and back. Inflammation and allergy. Drugs Target. vol. 7. hlm. 279-87.
Verleden GM, Vanaudenaerde BM, Dupont LJ, Van Raemdonck DE. 2006. Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med. vol. 174. hlm. 566-70.
Viasus D, Vidal G, Gudiol F, Carratala J. 2010. Statins for community-acquired pneumonia: current state of the science. Eur J Clin Microbiol Infect Dis. vol. 29. hlm. 143-152.
PNEUMONIA: adakah tempat untuk pemberian antiinflamasi ?
159
Vrancic M, Banjanac M, Nujic K, Bosnar M, Murati T, Munic V, et al. 2011. Azithromycin distinctively modulates classical activation of human monocytes in vitro. British Journal of Pharmacology. vol. 165. hlm. 1348-60.
Watson J. 2012. Raised inflammatory markers. BMJ. vol. 344. hlm. 1-5.
Wright HL, Moots RJ, Bucknall RC, Edwards SW. 2010. Neutrophil function in inflammation and inflammatory diseases. Rheumatology. vol. 49. hlm. 1618-31.
Wu Q, Shen W, Cheng H, Zhou X. 2014. Long – term macrolides for non – cystic fibrosis bronchiectasis : a systematic review and meta – analysis. Respirology. vol. 19. hlm. 321-29.
Xiao H, Qin X, Ping D. 2013. Inhibition of rho and rac geranylation by atorvastatin is critical for preservation of endothelial junction integrity. Plos One. vol. 8(3). hlm. 1-10.
Yanagihara K, Izumikawa K, Higa F, Tateyama M, Tokimatsu I, Hiramatsu K, et al. 2009. Efficacy of azithromycin in the treatment of community acquired pneumonia, including patients with macrolide resistant streptococcus pneumoniae infection. Inter Med. vol. 48. hlm. 527-35.
Yang XY, Wang LH, Farrar WL. 2008. A Role for PPARγ in
the regulation of cytokines in immune cells and cancer. PPAR Research. halm. 1-12.
Yano M, MatsumuraT, Senokuchi T, Ishii N, Murata Y, Taketa K, et al. 2007. Statins activate peroxisome proliferator-activated receptor through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase–dependent cyclooxygenase-2 expression in macrophages. Circ Res. vol. 100. hlm. 1442-51.
Zeilhofer HU and Schorr W. 2000. Role of interleukin-8 in neutrophil signaling. Current Opinion in Hematology. vol. 7. hlm. 178-82.
PNEUMONIA: Adakah tempat untuk pemberian antiinflamasi ?
160
Daftar Singkatan
KDO : 2-Keto-3-deoksi asam octanoat HMG-CoA : 3-hydroxy-3-methylglutaryl-CoA
AP-1 : Activator protein -1
ARDS : Acute Respiratory Distress Syndrome ACTH : adrenocorticotrophic hormone
IKK : aktivasi inhibitor I-κβ kinase ATS : American thoracic society APC : Antigen presenting cell APC : Antigen presenting cell
BPI : Bacterial permeability-increasing protein CRP : C reactive protein
CALC : Calsitonin
CREB : cAMP response element binding CAMPs : Cationic antimicrobial peptides CD : Cluster of differentiation CD : Cluster of differentiation
CAP : Community-acquired pneumonia
CURB-65 : Confusion, urea, respiratory rate, blood pressure, age
65 ≥ years
CHF : Congestive Heart Failure CBH : corticosteroid binding globulin
CRH : corticotrophin releasing hormone
CBP : CREB binding protein
CFR : crude fatality rate